[go: up one dir, main page]

MX2019003567A - Peptidos terapeuticos relacionados con mots-c. - Google Patents

Peptidos terapeuticos relacionados con mots-c.

Info

Publication number
MX2019003567A
MX2019003567A MX2019003567A MX2019003567A MX2019003567A MX 2019003567 A MX2019003567 A MX 2019003567A MX 2019003567 A MX2019003567 A MX 2019003567A MX 2019003567 A MX2019003567 A MX 2019003567A MX 2019003567 A MX2019003567 A MX 2019003567A
Authority
MX
Mexico
Prior art keywords
methods
mots
therapeutic peptides
peptides related
treating
Prior art date
Application number
MX2019003567A
Other languages
English (en)
Other versions
MX392374B (es
Inventor
Luo Wendy
Yao Yongjin
K Grindstaff Kent
MAGNAN Remi
Zeng Yan Liang
C Cundy Kenneth
Original Assignee
Cohbar Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cohbar Inc filed Critical Cohbar Inc
Publication of MX2019003567A publication Critical patent/MX2019003567A/es
Publication of MX392374B publication Critical patent/MX392374B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Oncology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)

Abstract

La presente invención se refiere a péptidos y análogos peptídicos y métodos para tratar una enfermedad metabólica, por ejemplo, obesidad, diabetes, métodos para tratar cáncer, métodos para tratar una enfermedad hepática, y métodos para modular el metabolismo del ácido graso.
MX2019003567A 2016-09-28 2017-09-27 Peptidos terapeuticos relacionados con mots-c. MX392374B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662401123P 2016-09-28 2016-09-28
PCT/US2017/053597 WO2018064098A1 (en) 2016-09-28 2017-09-27 Therapeutic mots-c related peptides

Publications (2)

Publication Number Publication Date
MX2019003567A true MX2019003567A (es) 2019-12-02
MX392374B MX392374B (es) 2025-03-24

Family

ID=60164788

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019003567A MX392374B (es) 2016-09-28 2017-09-27 Peptidos terapeuticos relacionados con mots-c.

Country Status (11)

Country Link
US (3) US11111271B2 (es)
EP (1) EP3519431A1 (es)
JP (1) JP7035033B2 (es)
KR (1) KR20190057110A (es)
CN (1) CN110072883A (es)
AU (1) AU2017336440B2 (es)
CA (1) CA3038292A1 (es)
IL (1) IL265463A (es)
MX (1) MX392374B (es)
TW (1) TW201819398A (es)
WO (1) WO2018064098A1 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7035033B2 (ja) * 2016-09-28 2022-03-14 コーバー、インコーポレイテッド 治療用ＭＯＴＳ－ｃ関連ペプチド
AU2019243724A1 (en) 2018-03-27 2020-10-29 Cohbar, Inc. Peptide-containing formulations
WO2019232740A1 (zh) * 2018-06-07 2019-12-12 汉义生物科技（北京）有限公司 一种用于防治糖尿病的药物组合物及其用途
MX2021008979A (es) * 2019-01-28 2021-11-12 Cohbar Inc Peptidos terapeuticos.
CN110818804B (zh) * 2019-10-21 2021-06-04 兰州大学 脑靶向肽及其在制备增强记忆药物中的应用
JP2023514584A (ja) * 2020-02-14 2023-04-06 ノースウェスタン ユニバーシティ 遺伝暗号の再プログラミングのため、長鎖炭素と環状アミノ酸が包含されるよう化学的基質を拡張する
CA3202532A1 (en) 2020-12-21 2022-06-30 Shek Hang Benedict LAW Peptide-linked drug delivery system
CN113440599A (zh) * 2021-08-11 2021-09-28 南京市妇幼保健院 MOTS-c肽及其衍生物在制备妊娠期糖尿病治疗药物中的应用
CN113876929B (zh) * 2021-11-22 2024-02-23 中国人民解放军陆军军医大学 肽MOTS-c在制备治疗帕金森药物中的应用
CN115444926A (zh) * 2022-05-10 2022-12-09 江南大学 MOTS-c肽及其衍生物在制备放射性肺损伤治疗药物中的应用
WO2023249904A1 (en) * 2022-06-20 2023-12-28 Arizona Board Of Regents On Behalf Of The University Of Arizona Compositions and methods for treating diabetes
US12064467B2 (en) * 2022-10-28 2024-08-20 Transdermal Biotechnology, Inc. Systems and methods for delivery of humanin or other peptides
CN119241659B (zh) * 2024-10-08 2025-09-19 西北大学 MOTS-c及其氨基酸突变多肽在伤口愈合方面的用途

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU597574B2 (en) 1986-03-07 1990-06-07 Massachusetts Institute Of Technology Method for enhancing glycoprotein stability
US5858351A (en) 1996-01-18 1999-01-12 Avigen, Inc. Methods for delivering DNA to muscle cells using recombinant adeno-associated virus vectors
US5846528A (en) 1996-01-18 1998-12-08 Avigen, Inc. Treating anemia using recombinant adeno-associated virus virions comprising an EPO DNA sequence
US6015709A (en) 1997-08-26 2000-01-18 Ariad Pharmaceuticals, Inc. Transcriptional activators, and compositions and uses related thereto
WO2001076532A2 (en) 2000-04-11 2001-10-18 Cogent Neuroscience, Inc. Compositions and methods for diagnosing and treating conditions, disorders, or diseases involving cell death
WO2001089583A2 (en) 2000-05-23 2001-11-29 Neurologix, Inc. Glutamic acid decarboxylase (gad)_delivery system for treating neurodegenerative diseases
US7588757B2 (en) 2001-03-14 2009-09-15 Genzyme Corporation Methods of treating Parkinson's disease using recombinant adeno-associated virus virions
WO2003052052A2 (en) 2001-12-17 2003-06-26 The Trustees Of The University Of Pennsylvania Adeno-associated virus (aav) serotype 9 sequences, vectors containing same, and uses therefor
US20070015238A1 (en) 2002-06-05 2007-01-18 Snyder Richard O Production of pseudotyped recombinant AAV virions
EP2368578A1 (en) 2003-01-09 2011-09-28 Macrogenics, Inc. Identification and engineering of antibodies with variant Fc regions and methods of using same
US20040258666A1 (en) 2003-05-01 2004-12-23 Passini Marco A. Gene therapy for neurometabolic disorders
TWI353991B (en) 2003-05-06 2011-12-11 Syntonix Pharmaceuticals Inc Immunoglobulin chimeric monomer-dimer hybrids
US8283151B2 (en) 2005-04-29 2012-10-09 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Isolation, cloning and characterization of new adeno-associated virus (AAV) serotypes
EP1857552A1 (en) 2006-05-20 2007-11-21 Cargill Incorporated Thermostable xylose isomerase enzyme
US7846445B2 (en) 2005-09-27 2010-12-07 Amunix Operating, Inc. Methods for production of unstructured recombinant polymers and uses thereof
PT1986661T (pt) 2006-02-08 2018-12-05 Genzyme Corp Terapia genética para a doença de niemann-pick tipo a
EP2007795B1 (en) 2006-03-30 2016-11-16 The Board Of Trustees Of The Leland Stanford Junior University Aav capsid proteins
US8292769B2 (en) 2006-11-22 2012-10-23 Lawson Jr Thomas Towles Transmission
WO2008153788A2 (en) 2007-05-30 2008-12-18 Albert Einstein College Of Medicine Of Yeshiva University Treatment of type 2 diabetes, metabolic syndrome, myocardial injury and neurodegeneration with humanin and analogs thereof
AU2008269954A1 (en) * 2007-06-29 2009-01-08 Centocor Ortho Biotech Inc. Anti- MCP-1 antibodies, compositions, methods and uses
CA2695374A1 (en) 2007-08-15 2009-02-19 Amunix, Inc. Compositions and methods for modifying properties of biologically active polypeptides
US7998928B2 (en) 2007-09-14 2011-08-16 The Regents Of The University Of California Method of treatment of type-1 diabetes with a humanin analogue
TWI541020B (zh) 2008-04-17 2016-07-11 巴克斯歐塔公司 生物活性胜肽
WO2009135165A2 (en) 2008-05-01 2009-11-05 The Regents Of The University Of California Small humanin-like peptides
US9217155B2 (en) 2008-05-28 2015-12-22 University Of Massachusetts Isolation of novel AAV'S and uses thereof
SG172291A1 (en) 2008-12-19 2011-07-28 Univ Indiana Res & Tech Corp Amide based glucagon superfamily peptide prodrugs
EP2553106A2 (en) 2010-03-29 2013-02-06 The Trustees Of The University Of Pennsylvania Pharmacologically induced transgene ablation system
EP3514232A1 (en) 2010-04-23 2019-07-24 University of Massachusetts Cns targeting aav vectors and methods of use thereof
WO2012009709A1 (en) * 2010-07-16 2012-01-19 Sudhir Paul Hiv cd4 binding site based covalent immunogen compositions
EP2634253B1 (en) 2010-10-27 2016-05-11 Jichi Medical University Adeno-associated virus virions for transferring genes into neural cells
BR112013021494B1 (pt) 2011-02-22 2021-09-08 California Institute Of Technology Vetor viral, polinucleotídeo isolado, uso de um vírus adeno-associado (aav) recombinante e método para produzir o mesmo
US20130123168A1 (en) 2011-06-17 2013-05-16 The Regents Of The University Of California Humanin and humanin-analogues for the management of atherosclerosis
BR112015023500B1 (pt) 2013-03-15 2021-01-12 The Regents Of The University Of California composição farmacêutica
US20160058881A1 (en) 2013-03-15 2016-03-03 Indiana University Research And Technology Corporation Prodrugs with prolonged action
KR20220119187A (ko) 2013-05-15 2022-08-26 리젠츠 오브 더 유니버시티 오브 미네소타 중추 신경계로의 아데노-연관 바이러스 매개 유전자 전달
JP6741591B2 (ja) 2014-05-02 2020-08-19 ジェンザイム・コーポレーション 網膜およびｃｎｓ遺伝子治療用ａａｖベクター
CN107106689A (zh) 2014-11-05 2017-08-29 沃雅戈治疗公司 用于治疗帕金森病的aadc多核苷酸
MA41451A (fr) 2015-02-04 2017-12-12 Univ Washington Constructions anti-tau
JP7035033B2 (ja) 2016-09-28 2022-03-14 コーバー、インコーポレイテッド 治療用ＭＯＴＳ－ｃ関連ペプチド

Also Published As

Publication number Publication date
KR20190057110A (ko) 2019-05-27
AU2017336440A1 (en) 2019-04-11
US11753445B2 (en) 2023-09-12
MX392374B (es) 2025-03-24
JP7035033B2 (ja) 2022-03-14
EP3519431A1 (en) 2019-08-07
US11332497B2 (en) 2022-05-17
WO2018064098A1 (en) 2018-04-05
TW201819398A (zh) 2018-06-01
IL265463A (en) 2019-05-30
CA3038292A1 (en) 2018-04-05
JP2020501514A (ja) 2020-01-23
AU2017336440B2 (en) 2022-06-02
US20220242912A1 (en) 2022-08-04
US20200181197A1 (en) 2020-06-11
US20210363187A1 (en) 2021-11-25
US11111271B2 (en) 2021-09-07
CN110072883A (zh) 2019-07-30

Similar Documents

Publication Publication Date Title
MX2019003567A (es) Peptidos terapeuticos relacionados con mots-c.
MX2015012034A (es) El péptido mots3 derivado de mitocondrias regula el metabolismo y supervivencia celular.
UY35548A (es) Péptidos terapéuticos para el tratamiento de trastornos metabólicos.
PE20181156A1 (es) Genes de ataxia de friedreich modificados y vectores para terapia genica
CO2017003048A2 (es) Moléculas de unión a antígeno biespecíficas activadoras de células t que se unen a cd3 y al receptor 1 de folato (folr1)
AR113881A1 (es) Composiciones y métodos para el tratamiento de desórdenes inmunes usando la cepa blautia
GT201500051A (es) Inhibidores de glucosilceramida sintasa
BR112021024236A2 (pt) Proteínas multiespecíficas
MX2018015853A (es) Anticuerpos multiespecificos frente a los grupos de diferenciacion 40 y 137 (cd40 y cd137).
EA201890530A1 (ru) Конъюгаты антитела к dll3 и лекарственного средства и способы их применения
EA201792573A1 (ru) Триспецифические связанные белки и способы их применения
EA201790548A1 (ru) Варианты комбинированной терапии анти-cd38 антителами
CL2020001495A1 (es) Composiciones y método para el tratamiento de enfermedades metabólicas
ECSP14001260A (es) Inmunoligantes biespecificos dirigidos contra tnf e il-17 referencia cruzada a solicitudes relacionadas
MX2017016253A (es) Anticuerpos para cd40.
EA201591762A1 (ru) Человеческие антитела к grem1
EA201990071A1 (ru) Композиция пептидной вакцины
MX2017014056A (es) Construcciones dirigidas a complejos de peptido e7 del subtipo 16 del virus de papiloma humano (hpv16-e7)/complejo principal de histocompatibilidad (mhc) y sus usos.
MX2015005252A (es) Metodo novedoso para tratar infarto cardiaco utilizando fragmento de hmgb1.
BR112017009552A8 (pt) Métodos para alvejar o controle transcricional em regiões de super-realçador
CR20170197A (es) Proteinas de variantes de secuencias de aminoacidos de cry1da1 activas para lepidópteros
BR112017012381A2 (pt) imunoterapia para doença angiogênica
MX2018006613A (es) Anticuerpos y moleculas que se unen inmunoespecificamente a btn1a1 y los usos terapeuticos de los mismos.
IL248668A0 (en) Pyrrolidine gpr40 modulators for the treatment of diseases such as diabetes
BR112018006866A2 (pt) compostos agonistas de ppar, composições farmacêuticas e métodos de uso dos mesmos